Drug-Drug Interaction Assessment of WXFL10203614 With Rifampicin, Itraconazole and Metformin: A Three-Cohort Phase I Study.
Abstract
To evaluate the effects of rifampicin and itraconazole on the pharmacokinetics (PK) of the Janus kinase 1 (JAK1) inhibitor WXFL10203614 and the effects of steady-state WXFL10203614 on metformin PK and safety. In this single-center, open-label, fixed-sequence, self-controlled Phase I study, 54 healthy participants were enrolled into three cohorts. Plasma and urine drug concentrations were measured using validated liquid chromatography-tandem mass spectrometry. Drug-drug interactions were assessed using geometric mean ratios and 90% confidence intervals for prespecified PK parameters. Rifampicin reduced WXFL10203614 systemic exposure by approximately 40% and shortened its elimination half-life by 39%, whereas itraconazole increased exposure by approximately 26%. Changes in Cmax were less pronounced, suggesting that altered systemic clearance contributed substantially to these interactions. Steady-state WXFL10203614 did not meaningfully alter metformin plasma exposure but reduced metformin renal clearance and cumulative urinary excretion by approximately 36% and 30%, respectively, consistent with an effect on renal tubular secretion involving MATE1/MATE2-K. No serious adverse events occurred, and most treatment-emergent adverse events were Grade 1. WXFL10203614 was sensitive to CYP3A induction, whereas the effect of CYP3A inhibition was modest. Concomitant use with strong CYP3A inducers should be avoided where possible. The reduced renal clearance and urinary excretion of metformin support consideration of MATE-mediated interactions when WXFL10203614 is co-administered with metformin or other relevant transporter substrates.